Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, when he expects the drug used in HIV PrEP, Truvada to come off patent.
The National Institute for Health and Care Excellence published a new medicines evidence summary for Truvada for pre-exposure prophylaxis (PrEP) in October 2016. According to this summary, Truvada, compound patents for tenofovir disoproxil and salts expires in July 2017, and tenofovir disoproxil fumarate expires in July 2018. A supplementary protection certificate has also been granted in relation to Truvada which expires in February 2020.